Organic Active Ingredients TRIZ Cases

Direct ocular delivery of L-lysine and ligustilide targets FHV-1 while avoiding the arginine depletion linked to oral treatment.

Chemical nucleotide modifications and targeting groups help siRNA resist cellular degradation while suppressing ANGPTL3 and improving lipid profiles.

Selective removal of damaged mitochondria is addressed through pharmaceutically usable naphthylamine solid forms with biological activity and safety.

To address AAV packaging limits for the oversized TTN gene, cardiac-specific vectors express SYNPO2L or inhibit MTSS1 to protect sarcomere function.

Structural parameter changes in Formula I compounds target TRPV4 while addressing toxicity, potency, and metabolic stability.

Hepatocyte-targeted RNAi agents inhibit GCK expression to reduce liver fat accumulation and mitigate MASLD and MASH progression.

Ponesimod modulates S1P1 to reduce corticosteroid treatment frequency and dose in patients with multiple sclerosis.

β-Alanine addresses the lack of safe NAMPT activators by raising NAD+ levels directly or through muscle-cell exosome miRNAs.

CL2A-linked ADCs deliver SN-38 or P2PDox before standard therapy to shrink resistant tumors with minimal toxicity.

Replacing the cap’s nucleophilic 3′-OH with an electron-withdrawing group supports efficient capping, translation, and intracellular mRNA stability.

Substituted pyridoisoquinoline compounds target VMAT2 while addressing rapid first-pass metabolism, short half-life, and frequent dosing.

Tailored lipid structures accelerate clearance from target tissues while preserving nucleic acid delivery for chronic dosing.

Controlled pH in a single unit dosage container limits glucose isomerization, reducing fructose and 5-HMF during storage.

Combining Lactobacillus probiotics with oligosaccharides targets dysbacteriosis and supports gut and immune maturation in children.

Qβ capsid and 3WJ RNA scaffolds package siRNA to silence DNA-repair genes, helping sensitize radioresistant glioblastoma cells before radiotherapy.

Similar lipoprotein structures hinder direct Lp(a) drug targeting; LPA siRNA degrades mRNA to inhibit expression and lower serum Lp(a).

Blocking miR-17 with modified oligonucleotides slows cyst growth, improves kidney function, and delays polycystic kidney disease progression.

Structural variation across benzothiazepine derivatives targets ASBT/LBAT potency, selectivity, and bioavailability for bile acid reabsorption control.

EL2-binding proteins selectively recognize CLDN6 on cancer cells, supporting apoptosis, ADCC, and CDC while inhibiting tumor growth.

Rapid body-temperature gelation helps maintain mucosal elevation during ESD while supporting bleeding reduction and wound healing.

Microbiota fermentation of beta1,3′-galactosyllactose-enriched GOS helps restore immune cell frequencies and vaccine response after DON exposure.

Frequent TKI injections can cause discomfort and side effects; a hydrogel implant mediates sustained ocular delivery while limiting systemic exposure.

Positively charged amino acid nanopolymers use controlled surface chemistry to inhibit SARS-CoV-2 with low cytotoxicity and water dispersibility.

Anaerobic Megasphaera strains are isolated and screened for acid production, supporting pharmaceutical compositions for metabolic disease treatment.

Aramchol targets liver cells to reduce collagen production, inhibit hepatic fibrosis, and address toxicity concerns in current treatments.

Novel CDRs target an eHSP90α epitope to address inhibitor stability challenges and reduce tumor growth and desmoplasia.

An optimized anti-CLDN18.2 antibody and cleavable linker help stabilize the conjugate and deliver cytotoxins to tumor cells.

Specific heterocyclic rings and substituent changes tune GPR39 antagonists for improved receptor specificity across metabolic, gastrointestinal, and cancer disorders.

Drug-resistant NSCLC is addressed with seleno-amino acids that reduce Treg infiltration, promote TH17 differentiation, and inhibit tumor growth.

Disulfide bridges stabilize branched peptide nanostructures that protect nucleic acids, improve cellular uptake, and reduce toxicity.

These tetrahydroquinolinone compounds modulate RORγ to reduce Th17 activity and inflammation linked to autoimmune disorders.

A mortise-tenon light guide needle couples low-power LED photodynamic therapy with controlled exposure to limit tooth and tissue damage.

Limited checkpoint response and resistance in MSI-H/dMMR cancers motivate bicyclic pyrimidinones that inhibit WRN helicase and ATPase activity.

A 3–42-day washout or reduced dosing helps limit dangerous side effects from posaconazole accumulation before CYP3A4 treatment.

Novel compounds selectively target ROCK1 or ROCK2 to reduce off-target kinase activity and cytotoxicity in ROCK-mediated treatment.

Protease cleavage separates receptor binding and signaling domains, helping limit basal activity and adverse events while preserving therapeutic control.

Existing HPK1 modulators may provide insufficient cancer treatment, so substituted pyrrolo[2,3-b]pyrazines target HPK1 activity and tumor growth.

CD73 inhibitors reduce adenosine production to counter immunosuppression and sensitize tumors to chemotherapy and immunotherapy.

MCC and DCPA combine with Compound (I) to support immediate release, tablet strength, stability, and reproducible ERα down-regulation.

Novel fused-ring compounds inhibit MGAT2 in the small intestine to reduce fat absorption, weight gain, insulin resistance, and fatty liver formation.

An injectable PLGA-based leuprolide depot forms in situ to sustain ovarian suppression and support concurrent endocrine therapy for up to 3 months.

Broccoli extract is purified by chromatography and hydrolyzed with oxalic acid to isolate a polysaccharide that stimulates innate immunity.

Impaired cellular energy, oxidative stress, and calcium imbalance drive disease; quinazolinones target mitochondrial dysfunction pharmacologically.

High-viscosity pharmaceutical slurries can stream or clog; multi-port dispensing controls droplet spacing for uniform pellets and less product loss.

Vaginal gels can leak and complex products hinder adherence; dissolvable films deliver antiviral drugs on demand with controlled release.

Prebiotic nutrition helps probiotics persist on biocompatible microspheres, limiting pathogen colonization in the gastrointestinal tract.

Cationic lipid particles shield nucleic acids from plasma nucleases while supporting intracellular delivery and improved tolerability.

An ester prodrug improves inotodiol solubility and stability, supporting small-intestinal absorption and large-intestinal release of the active compound.

Small-molecule compounds block PAC1 plasma-membrane and endosomal ERK signaling, addressing peptide degradation and BBB limitations.

Defined arabinogalactan structure helps reduce polyphenol astringency in beverages, medicaments, and other oral products while preserving antioxidant action.

This case pairs OTC-encoding mRNA with ionizable lipid nanoparticles to improve stability, translation, and delivery to hepatocytes.

This case combines vemurafenib and GDC-0973, using amorphous forms to extend response and delay resistance in metastatic melanoma.

This case shows how renal and hepatic status guide atogepant dosing to balance migraine prevention efficacy with treatment safety.

Oral beta-glucan and avenanthramide compositions reduce inflammation biomarkers while limiting broad immune suppression and side effects.

This case combines L-arginine and forskolin in a topical base to support nitric oxide, blood flow, and smooth muscle relaxation.

Modular urolithin derivatives enhance mitochondrial activity while addressing neuronal health limitations in disease treatment.

This case uses non-covalent peptide complexes and micro or nano structures to balance aqueous drug stability with sustained release.

This case uses a complex oil phase and controlled viscosity to stabilize concentrated oxymetazoline cream while supporting skin delivery.

Cleavable peptide-linked polymers pair PD-L1 inhibitors with anticancer agents to sustain tumor exposure and limit organ accumulation.

A glycosyl bridge and 20 kDa PEG stabilize liquid mutant FGF-21 conjugates for longer action and preserved biological activity.

Novel Formula (I) compounds isolate CBP/p300 bromodomains as targets, addressing the difficulty of blocking transcription factors.

This case uses Enterococcus faecium and L-dopa to sustain gut dopamine delivery and enhance vaccine protection.

Cyclic ether PDE2 inhibitors improve CSF penetration and tissue permeability.

This case pairs CLDN6/CLDN9 antibodies with a spiro-modified PBD payload to improve internalization and tumor-cell killing.

Chemical NLRP3 agonists and partial agonists boost innate immune signaling in cancers with insufficient immune response.

Isotonic nanoparticle cores help stabilize cellular membranes for targeted delivery.

This case uses weekly gedatolisib for three weeks and a one-week break to address toxicity while treating endocrine-resistant breast cancer.

Glycerol monooleate and triglyceride carriers form a biodegradable depot that maintains effective drug levels after injection.

Bis-allylic deuterium substitution strengthens C-D bonds, helping stabilize PUFAs and limit toxic oxidation by-products.

Folic acid-modified hydroxyalkylated cyclodextrin targets folate receptors, enhancing uptake and apoptosis in leukemia cells.

Reduced binder content and melt processing support high-load GnRH antagonist formulations with rapid dissolution.

Propylene glycol dissolves hydrophobic ingredients while carbohydrates support beverage dispersion and limit lipid-phase recombination.

Polystyrene sulfonate-based compounds inhibit Factors B, D, and H to address inflammation, thrombosis, and immune dysfunction.

Alpha-polyglutamated raltitrexed liposomes bypass intracellular conversion to improve tumor-cell killing and reduce normal-tissue toxicity.

Reflux extraction, filtration, distillation, and redox processing remove contaminants and control CBN formation for stable dosing.

This case combines ALK5 inhibitors with glucocorticoids to block TGF-beta signaling, support regeneration, and counter muscle wasting.

This case examines S1P receptor agonism with mocravimod to induce tumor-cell apoptosis without hematopoietic stem cell transplantation.

This HCC case combines LAG-3 and PD-1 pathway inhibition with anti-angiogenesis treatment to improve response and survival.

This case uses darapladib to suppress myofibroblast activation while restoring moisture, pH, skin thickness, and adipocyte area.

The case uses L1CAM inhibition to target slow-cycling MetCSCs, reduce metastatic spread, and restore chemotherapy sensitivity.

Small molecules targeting CRL4CRBN degrade GSPT1 while addressing poor stability and bioavailability in nucleic acid approaches.

Dorsomorphin and GSK3 inhibitors help expand desired T, NK, and NKT subsets while preserving persistence and anti-tumor activity.

This case uses slow dissolution and periodic dosing to limit plasma peaks while preserving ovulation inhibition without estrogen.

This case applies modular scaffolds and localized substituent changes to balance KDM5 efficacy, specificity, and compound synthesis.

This case examines pyridinylacetamide derivatives that selectively activate Nav1.1 channels to modulate seizures in refractory epilepsy.

This case uses substituted bicyclic heteroaromatics to inhibit TEAD proteins while balancing potency, solubility, and toxicity.

Combining a DDX54 inhibitor with immunotherapy suppresses immune evasion and supports tumor-infiltrating lymphocyte activity.

PSAT1 activators promote cardiomyocyte growth and reduce oxidative stress.

Mannose-siRNA conjugates target CD206 receptors on macrophages, improving uptake and gene silencing in living subjects.

This case uses azolo compounds to normalize collagen I mRNA in TGFβ-activated fibroblasts and limit fibrotic fiber formation.

Formula I selectively activates AT2R, offering anti-fibrotic and cardiovascular treatment potential beyond AT1R blockade.

Substituted tricyclic compounds selectively inhibit PARP1 to reduce PARP2 and TNKS1/2 off-target toxicity.

Formula I heterocyclic compounds form insoluble depots to extend therapeutic levels, reduce dosing frequency, and limit side effects.

A single oral MK-0677 dose measures peak GH and IGF-I, reducing complex supervision and painful injections.

This case uses modified oligonucleotides and RNase H degradation to reduce Lp(a) while avoiding frequent invasive apheresis.

This case pairs selective PARP1 inhibition with AR signaling blockade for metastatic and resistant prostate cancer treatment.

This case uses TRAC and FOXP3 editing plus controlled expansion to preserve Treg function and protect beta cells in type 1 diabetes.

This case uses graded oligosaccharides in animal feed to increase beneficial metabolites and reduce harmful gut compounds.

Dynamic cooling and vacuum control preserve GQ1001 ADC stability during freeze-drying.

This case uses PARP1-selective molecular targeting to retain antitumor activity while reducing adverse events linked to PARP2 inhibition.

Pyridopyrazine compounds inhibit serine/threonine and lipid kinases to simultaneously control multiple signaling pathways, addressing single-target limitations.

Single-molecule dual-activity compounds replace separate bronchodilators to simplify respiratory formulations while maintaining therapeutic efficacy.

Flowable risperidone composition transforms into a biodegradable thermoplastic polymer implant, eliminating the lag phase and reducing injection volume.

Targeting DYRK1B kinase bypasses Smoothened resistance mechanisms to suppress GLI-mediated tumor growth.

Sulfated chitosan nanogels reduce HIV toxicity and improve adherence by enabling lower effective doses.

Selective piperazinyl modulators target the MIP-1α/CCR-1 interaction to reduce inflammatory responses without causing side effects.

N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds selectively inhibit CC chemokine receptor 6.

Encapsulating cabazitaxel in polyalkyl cyanoacrylate nanoparticles overcomes hydrophobic solubility limits while reducing systemic toxicity.

Imidazopyrazine compounds inhibit spleen tyrosine kinase activity, resolving incomplete disease control and side effects in autoimmune treatment.

Thiazolidinone compounds inhibit CETP to raise HDL-C and lower LDL-C, addressing safety issues in existing therapies.

Substituted heterocyclic compounds treat mental disorders by balancing dopamine and serotonin activity to reduce extrapyramidal side effects.

Formula I compounds bind NR2B receptors with high selectivity.

Synergistic anti-CD38 antibody and melphalan therapy reduces bone lysis and Protein M concentration in multiple myeloma models.

Nitrogen-containing heterocycle derivatives with specific substituents provide potent TrkA kinase inhibition for treating pain and cancer.

Combining antineoplastic antibiotics with BCL-2 inhibitors disrupts NPM1c/PML complexes to induce cellular senescence.

Pyrazolopyrimidine derivatives inhibit CaMKII to address the lack of effective treatments for atrial fibrillation and heart failure.

Ibudilast inhibits phosphodiesterases to suppress glial activation, reducing brain volume loss in neurodegenerative disease treatment.

Segmented detection methods using fluorescent probes and PCR primers identify mutant ALK kinases in biological samples.

A nucleic acid compound incorporates half-life extension motifs to enhance cellular uptake and stability.

Combines SOS1 and MEK inhibitors to target cancer cells with primary KRAS G12C mutations.

Conjugated polycationic polymers sequester circulating nucleic acids, preventing Toll-like receptor activation and reducing inflammatory mediator levels.

Combining aspirin with fumaric acid esters increases bioavailability, reducing cutaneous flush side effects while maintaining treatment efficacy.

Combination of Rhodiola and Astragalus extracts maintains neurite length in neurodegenerative disease models.

Total flavonoid extract from Gynura formosana Kitam. isolates rutin via enzymatic hydrolysis and macroporous resin chromatography.

Citrate buffer paired with lysine stabilizes TNFR:Fc fusion protein formulations against physical degradation.

Segmenting the TNF-alpha protein into distinct epitopes reduces infection susceptibility and allergic reactions while maintaining therapeutic efficacy.

3α-ethynyl-3β-hydroxyandrostan-17-one oxime selectively inhibits steroid modulation of GABAA receptors.

Controlled heating converts unstable 13-Z lycopene into stable 5-Z and 9-Z isomers, improving bioavailability while maintaining composition stability.

Erythroid RNF41 expression levels predict lenalidomide responsiveness in non-del(5q) MDS patients.

A topical diclofenac composition with enhanced skin penetration excipients reduces application frequency from multiple daily doses to once daily.

S-adenosylmethionine compounds inhibit monoamine oxidase B through the one-carbon cycle, addressing inefficient Alzheimer's disease drug development.

Heteroaryl alkaloid aminoester derivatives act as potent muscarinic receptor antagonists to produce persistent bronchodilation in respiratory tissues.

Dynamic HARQ timing aligns with MBSFN periodicity to prevent relay nodes from missing acknowledgments during simultaneous transmission and reception.

Topical nitrofurantoin composition addresses recurrence of foot infections through localized antimicrobial delivery.

BR297 and BR351 modulate GABA A receptors, overcoming SSRI treatment resistance.

Segmented compartments deliver pH-modifying agents and synbiotics to treat infections while preserving healthy flora.

Novel bile acid conjugates modulate farnesoid X receptor activity to treat inflammatory bowel disease.

Ultra-low concentration PCV2 ORF-2 antigens stimulate protective immunity in young piglets despite maternal antibody interference.

Formula A compounds selectively inhibit Nav1.7 channels to treat pain and cough while sparing cardiac Nav1.5 channels.

A nitrogen-containing aromatic heterocyclic compound inhibits aldosterone synthetase to lower plasma aldosterone levels.

Substituted quinazoline derivatives overcome poor bioavailability and toxicity of existing nucleoside analogues by modulating DNA methylation patterns.

Small molecule splicing modulators overcome oligonucleotide limitations by enabling oral bioavailability and blood-brain barrier penetration.

SP101 modifies the chemical structure of Gefitinib to overcome T790M-mediated drug resistance and cancer stemness in non-small cell lung carcinoma.

Novel 2-heteroaryl benzothiophene derivatives cross the blood-brain barrier to selectively bind amyloid deposits.

Asymmetric siRNA complexes inhibit angiogenesis by targeting ANGPT2 and PDGFB, avoiding geographic atrophy from VEGF inhibitors.

Conjugating exatecan to anti-HER2 antibody via specific linker delivers drug selectively to tumor cells while minimizing side effects on normal tissues.